Article Sidebar
Published:
Mar 21, 2008Keywords:
Article Details
The author(s) retain copyright on work published by AOSIS unless specified otherwise.
Licensing and publication rights
Author(s) of work published by AOSIS are required to grant AOSIS the unlimited rights to publish the definitive work in any format, language and medium, for any lawful purpose. AOSIS requires journal authors to publish their work in open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.
The authors retain the non-exclusive right to do anything they wish with the published article(s), provided attribution is given to the applicable journal with details of the original publication, as set out in the official citation of the article published in the journal. The retained right specifically includes the right to post the article on the authors’ or their institution’s websites or in institutional repositories.
Previously published work may have been published under a different licence. We advise the community that if they would like to reuse the work to consult the applicable licence at article level.
Note: If you need to comply with your funding body policy, you can apply for the CC BY license after your manuscript is accepted for publication.
Main Article Content
Investigation into the prescribing patterns and cost of antidiabetic medicine in South Africa
Abstract
The general objective of this study was to investigate the prescribing patterns and cost of antidiabetic medicine in the private health care sector in South Africa by using a medicine claims database. A quantitative, retrospective drug utilisation study was performed on data for the year 2004. Oral antidiabetic medicine accounted for 81% (n =
143 447) and 39% (R29 734 360.61) respectively of the total prevalence and cost of all antidiabetic products prescribed. Metformin was the most frequently prescribed oral antidiabetic medicine, with an average cost of R58.42 (SD = 31.78). The three most frequently prescribed classes of insulin (insulin lispro; soluble insulin and isophane;
and soluble insulin aspartame and protamine) together accounted for 63% of all the insulin prescribed, and 67% of the total cost of prescribed insulin. Almost 39% (n = 62 717) of the “combination therapy” prescriptions were for a sulfonylurea in combination with a biguanide plus at least one other antidiabetic product. A trend towards combination
therapy away from monotherapy was observed. Prescribed Daily Doses (PDDs) calculated for oral antidiabetic medicines were more or less in line with recommended treatment guidelines. Drug utilisation review studies thus provide valuable insight into the treatment of diabetes – indicating areas of possible over- and under usage, providing
decision-makers with critical information to curb unnecessary costs.
Keywords: antidiabetic medicine; South African private health sector; retrospective drug utilisation review; prescribing patterns; medicine cost
Health SA Gesondheid Vol. 12 (3) 2007: pp. 26-36
